• Group sales revenue of $5.3m, down 19% QoQ and 13% pcp
• Oli6® Nutritionals delivered $4.0m in Q2 sales, flat QoQ
• Practitioner channel revenue down 48% QoQ to $1.3m
• International revenue softer due to timing of orders and shipments
• Net operating cash inflow of $0.8m, cash at $3.1m

Nuchev Limited reported its Q2 FY26 results, with group sales revenue of $5.3m, down 19% quarter-on-quarter and 13% year-on-year. The Oli6® Nutritionals division delivered $4.0m in Q2 sales, flat quarter-on-quarter, supported by consistent performance across major Australian retail partners. The Practitioner channel revenue was $1.3m, down 48% quarter-on-quarter, reflecting softer trading conditions. International revenue was also softer in Q2, largely due to the timing of orders and shipments, particularly in Vietnam and China CBEC. The company continued to progress new product development (NPD) initiatives across both the Oli6® and Practitioner divisions. Net operating cash inflow for the quarter was $0.8m, with cash at 31 December 2025 standing at $3.1m. The company remains debt-free with unused financing facilities, providing flexibility to support ongoing operations and growth initiatives. Nuchev's CEO, Nathan Cheong, stated that the company's priority remains disciplined execution across channels, continued investment in the innovation pipeline, and delivering high-quality nutritional, immunity and wellness products for its customers.

The company remains focused on disciplined execution across its core channels, continued progression of its NPD pipeline across Oli6® and Practitioner products, and exploring opportunities to enhance scale and margin outcomes across ANZ and international markets over time.